📰 Poster Section News
Page 9 - Poster Section News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Poster Section. Real-time updates on events, politics, business and more.
April 7, 2022
Initial data from the Phase 1 dose escalation part of the OBT076 trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable...
April 6, 2022
/PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment...
March 28, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
March 24, 2022
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
March 24, 2022
/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...
March 22, 2022
Specific TLR3-agonist TL-532 induces lifelong anti-tumor auto-vaccinationData also showed cross-immunity against unrelated cancersThese results confirm two new properties for TL-532, which showed proof-of-concept of inducing tumor cell death by apoptosis and reversing resistance to immune checkpoint inhibitors in pr...
March 16, 2022
/PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology, announced today...
March 16, 2022
/PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology, announced today...
March 15, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
March 15, 2022
/PRNewswire/ -- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors,...